OR WAIT null SECS
December 15, 2016
Oxford Genetics received £1.61 million from Innovate UK to explore computational and synthetic biology approaches for optimized mammalian bioproduction.
December 02, 2016
Quantitative and qualitative tools allow better understanding of mixing in a single-use bioprocessing system.
November 23, 2016
Oxford Genetics has been awarded a grant to develop packaging cell lines for virus bioproduction and will work in collaboration with the University of Oxford to generate cell lines for the scalable manufacture of retrovirus and lentivirus vectors.
November 17, 2016
Avecia is adding drug substance capacity at its Milford, MA manufacturing site.
November 02, 2016
Reliable, high-quality products require innovative analytics and production.
Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.
The biosimilar pathway permits licensure based on less than full clinical data.
November 01, 2016
Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.
October 24, 2016
FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.
Catalent invests $34 million to add a 2 x 2000-L single-use bioreactor system and laboratory space in Madison, WI.